Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Indivior
AddedMar 20, 2024
UpdatedJul 9, 2026
Indivior

Indivior

Public

Global medical company developing buprenorphine drugs for opioid dependence and co-occurring disorders. Operating in 40+ countries.

HQ
Chesterfield, VA, US
Overview
Compare
Employees
Website

Indivior Plc, founded in Chesterfield, Virginia, is a global medical organization dedicated to developing, manufacturing, and selling buprenorphine-based prescription drugs aimed at treating opioid dependence and co-occurring disorders. The company's core mission is to provide effective treatment options for opioid use disorder, addiction, and schizophrenia. Indivior's product lineup includes SUBLOCADE injection for subcutaneous use, SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in over 40 countries, focusing on addressing the global opioid crisis.

Notable individuals affiliated with Indivior include its experienced leadership team and board members who have extensive backgrounds in pharmaceuticals and healthcare. The company has attracted significant investment from stakeholders committed to combating the opioid epidemic. Key achievements include the successful market introduction of its flagship products, SUBLOCADE and SUBOXONE, which have become critical tools in opioid dependence treatment. Indivior's impact is profound, providing essential medications to millions globally and contributing to public health efforts to manage and reduce opioid addiction.

Indivior - Similar Companies

Recover Together logo

Recover Together

Assertio Holdings logo

Assertio Holdings

Aquestive Therapeutics logo

Aquestive Therapeutics

aquestive.com

Elite Pharmaceuticals logo

Elite Pharmaceuticals

elitepharma.com

Manhattan Pharmaceuticals logo

Manhattan Pharmaceuticals

Ivrea Pharmaceuticals logo

Ivrea Pharmaceuticals

Braeburn logo

Braeburn

braeburnrx.com

Novartis Pharma logo

Novartis Pharma

Sapir Pharmaceuticals logo

Sapir Pharmaceuticals

DemeRx logo

DemeRx

demerx.com

Supernus Pharmaceuticals logo

Supernus Pharmaceuticals

supernus.com

PleoPharma logo

PleoPharma

pleopharma.com

Opiaid logo

Opiaid

opiaid.tech

DMK Pharmaceuticals logo

DMK Pharmaceuticals

Amneal Pharmaceuticals logo

Amneal Pharmaceuticals

amneal.com

Indivior - Quick Facts

Who are Indivior's competitors?

Companies similar to Indivior include Recover Together, Assertio Holdings, Aquestive Therapeutics and Elite Pharmaceuticals.

Where is Indivior's headquarters located?

Indivior's headquarters is located in Chesterfield, VA, US.

How many employees does Indivior have?

Indivior has 1,000 employees as of Feb 6, 2024.

Indivior - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Biotech
Unique IDs
  • secCik: 0001625297
  • ticker: INDV
NAICS
  • 621000Ambulatory Health Care Services
  • 621500Medical and Diagnostic Laboratories
  • 621510Medical and Diagnostic Laboratories
  • 621511Medical Laboratories
  • 620000Health Care and Social Assistance
SIC
  • 8070Medical And Dental Laboratories
  • 8071Medical Laboratories
  • 8000Health Services
Show 2 more industry codes
SIC
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified